Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS

A Phase I Double-Blind Study to Evaluate the Safety and Immunogenicity of HIV Prime/Boost Vaccine Using DNA and MVA for HIV-1/AIDS

This is a randomized, double-blind placebo-controlled dose-escalation clinical trial to evaluate the safety and the immunogenicity of DNA and modified vaccinia virus Ankara (MVA) HIV-1 vaccines in subjects receiving stable highly active antiretroviral therapy (HAART) who have an HIV-1 RNA < 50 copies/mm3 and CD4+ T cells count ≥ 350 cells/mm3.

Study Overview

• Status: Unknown
• Conditions: Acquired Immunodeficiency Syndrome
• Intervention / Treatment: Biological: Saline Solution; Biological: D-GPEi; Biological: M-GPE

Detailed Description

HIV-infected patients treated with antiretroviral therapy for prolonged periods of time may show decreased levels of HIV-specific immune responses. In these patients, a prime-boost vaccine strategy may induce both humoral and cell-mediated immunity. The hypothesis of this study is that the vaccine strategy selected will be both safe and immunogenic in the patient population being tested.

Patients continue antiretroviral medications throughout the course of this study. Three groups of patients receive dose-escalation (0.5mg, 2mg or 4mg) intramuscular injections of DNA vaccine (D-GPEi) respectively, the other three groups of patients receive dose-escalation (3×10^7pfu, 1×10^8pfu or 3×10^8pfu) intradermal injections of MVA vaccine (M-GPE), two weeks post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of immunization will begin. After the maximum tolerated dose of DNA and MVA is identified, DNA prime/ MVA boosting will be tested in another two groups of patients. Lower or the maximum tolerated dose of D-GPEi was used at week 0 and 1, lower or the maximum tolerated dose of M-GPE was used at week 2 and 3, patients are monitored for safety 72 hours after each immunization. In addition, each patient records adverse events in a diary. Patients have regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic assessments. The induction of HIV-specific responses will be measured.

• Study Type: Interventional
• Enrollment (Anticipated): 56
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Recruiting
    • Beijing Ditan Hospital of Capital Medical University
    • Contact: Xingwang Li; Phone Number: 15611973658; Email: ditanlxw@yahoo.com.cn
    • Principal Investigator: Xingwang Li
    • Sub-Investigator: Rongmeng Jiang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Are willing to participate this study and available for follow-up for the duration of the study.
• Men and women aged 18-50 years.
• Are HIV-positive.
• Have been taking stable anti-HIV drugs for at least 6 months.
• CD4 count ≥ 350 cells/mm3
• Plasma viral load < 50 copies/ml.
• Willing to use acceptable forms of contraception at least 21 days prior to first vaccination until 56 days after the last vaccination.

Exclusion Criteria:

• Pregnancy or breast-feeding.
• History of previous vaccination with an HIV-1 vaccine.
• Use of immunoinhibitory agents, such as corticosteroids or cytotoxic drugs by oral administration, injection route or inhalation route within 6 months of study entry (But corticosteroids used for allergic rhinitis and skin topical application of corticosteroids were not included); Use of immunomodulatory agents including but not limited to interleukin-2(IL-2） and granulocyte-macrophage colony-stimulating factor (GM-CSF) within 30 days of study entry.
• Use of blood products within 3 months of study entry.
• Use of other experimental drugs within 3 months of study entry.
• Any immunization within 3 months of study entry.
• Comply with any of the following items： Active pulmonary tuberculosis； History of serious adverse reaction to other vaccines； Serious asthma； Have untreated thyroid disease; Syphilis
• Laboratory values（Comply with any of the following items）:

Hemoglobin < 100 g/L (male subjects)，<90 g/L (female subjects)； Absolute neutrophil count ≤ 1000 cells/mm3； Serum creatinine ≥15 mg/L，endogenous creatinine clearance rate <50 ml/min； alanine aminotransferase（ALT）, aspartate aminotransferase(AST) ≥3× upper limit of normal range； Total bilirubin ≥2× upper limit of normal range

• Clinically significant electrocardiogram changes.
• Hypertension ( If it is well controlled by medication and is less than 150/100mmHg , should not be excluded) and other cardiac disease；
• Any medical, psychiatric, social condition, occupational reason judged by the investigator that would limit the evaluation of a subject.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lower dose DNA or Placebo; 2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: D-GPEi; D-GPEi is used in Arm A,B,C,G and H.
Experimental: Medium dose DNA or Placebo; 2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: D-GPEi; D-GPEi is used in Arm A,B,C,G and H.
Experimental: High dose DNA or Placebo; 2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: D-GPEi; D-GPEi is used in Arm A,B,C,G and H.
Experimental: Lower dose MVA or Placebo; 100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: M-GPE; M-GPE is used in Arm D,E,F,G and H
Experimental: Medium dose MVA or Placebo; 100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: M-GPE; M-GPE is used in Arm D,E,F,G and H
Experimental: High dose MVA or Placebo; 300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: M-GPE; M-GPE is used in Arm D,E,F,G and H
Experimental: Low dose DNA+MVA or Placebo control; The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: D-GPEi; D-GPEi is used in Arm A,B,C,G and H.; Biological: M-GPE; M-GPE is used in Arm D,E,F,G and H
Experimental: High dose DNA+MVA or Placebo control; The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3	Biological: Saline Solution; Saline Solution is used as control in all arms.; Biological: D-GPEi; D-GPEi is used in Arm A,B,C,G and H.; Biological: M-GPE; M-GPE is used in Arm D,E,F,G and H

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence, intensity and relationship to vaccination of local and systemic adverse events	To evaluate the safety and tolerance of a DNA and a replication-defective MVA vaccine expressing HIV-1 gag-pol and env in HIV-1 infected subjects on highly active antiretroviral therapy. Frequency and severity of adverse events, laboratory abnormalities, and local and systemic reactogenicity signs and symptoms following vaccinations	8 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity of vaccine	Changes in CD4+ and CD8+ T-cell counts pre- and post-immunization and between the vaccine and placebo groups Changes in viral load pre- and post-immunization and between the vaccine and placebo groups Magnitude and breadth of HIV-1 specific CD8+ T cell responses as determined by interferon-γ(IFN-γ) enzyme-linked immunospot (ELISPOT) using overlapping HIV peptides for gag, pol and env Changes in HIV-1 Gp160-specific antibody responses pre- and post-immunization and between the vaccine and placebo groups	14 months

Collaborators and Investigators

• Sponsor: Centers for Disease Control and Prevention, China
• Collaborators: Beijing Ditan Hospital; National Institutes for Food and Drug Control, China
• Investigators: Principal Investigator: Ke Xu, Ph.D, National Institute for Viral Disease Control and Prevention, China CDC; Principal Investigator: Xingwang Li, M.D., Beijng Ditan Hospital of Capital Medical University; Principal Investigator: Rongmeng Jiang, M.D., Beijng Ditan Hospital of Capital Medical University; Principal Investigator: Yi Zeng, National Institute for Viral Disease Control and Prevention, China CDC; Principal Investigator: Xia Feng, Ph.D, National Institute for Viral Disease Control and Prevention, China CDC

Study record dates

Study Major Dates

• Study Start: June 1, 2013
• Primary Completion (Anticipated): March 1, 2014
• Study Completion (Anticipated): August 1, 2014

Study Registration Dates

• First Submitted: June 16, 2013
• First Submitted That Met QC Criteria: June 16, 2013
• First Posted (Estimate): June 19, 2013

Study Record Updates

• Last Update Posted (Estimate): June 20, 2013
• Last Update Submitted That Met QC Criteria: June 19, 2013
• Last Verified: June 1, 2013

More Information

Terms related to this study

• Keywords: DNA; HIV; Vaccine; Therapeutic; MVA
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immune System Diseases; Slow Virus Diseases; HIV Infections; Acquired Immunodeficiency Syndrome; Immunologic Deficiency Syndromes
• Other Study ID Numbers: CDCPChina001